Psychedelics can precipitate a manic episode in undiagnosed bipolar disorder, and the risk is concentrated in the population least likely to recognize itself. The mania induction risk after psilocybin or LSD in mixed populations is estimated at 4 to 9 percent, with substantially higher risk in those with an underlying bipolar spectrum disorder (Gard et al., 2024). This is why every major clinical trial, MAPS, COMPASS Pathways, Usona, Yale, Johns Hopkins, excludes both Bipolar I and Bipolar II at intake.
The founders I work with rarely screen themselves as bipolar. They screen themselves as ambitious. As visionary. As people who can run on four hours of sleep and feel sharper, not foggier, for it. As people who get a wild idea at 2 am and execute it by Friday. That presentation is not always pathological. Sometimes it is just an unusually high-functioning person. Sometimes it is Bipolar II hypomania, undiagnosed, often for a decade or more, because the hypomanic state feels like the person's best self.
This article is about the screening that should happen before a psychedelic session, why retreat operators often skip it, what the validated instruments actually ask, and what to do if your screening comes back positive. For interaction-specific safety, see SSRIs and psychedelics and the preparation framework in psilocybin therapy preparation.
- Bipolar I prevalence is 0.6 percent and Bipolar II is 0.4 percent in the general US adult population, per the DSM-5 reference data from Merikangas et al. 2007.
- Bipolar II is misdiagnosed as recurrent unipolar depression for an average of 10-plus years, because hypomanic episodes feel productive rather than ill (Hirschfeld, MDQ research).
- Mania induction risk after psilocybin or LSD in mixed populations is roughly 4 to 9 percent, with higher rates in those who already meet bipolar criteria (Gard et al., 2024).
- MAPS, COMPASS, Usona, Yale, and Johns Hopkins trials exclude both Bipolar I and II, and most also exclude first-degree family history.
- The Aaronson 2024 JAMA Psychiatry trial showed that psilocybin can be carefully studied in Bipolar II depression with intensive monitoring, but the result is not a green light for retreat-context use.
- Founder presentations of "ambitious, visionary, sleep-light, idea-rich" overlap meaningfully with hypomania. A validated screening tool such as the MDQ or HCL-32 takes 10 minutes and is the minimum responsible filter.
Why Does Every Major Psychedelic Trial Exclude Bipolar Disorder?
Every Phase 2 and Phase 3 psychedelic trial, including MAPS MDMA-PTSD, COMPASS Pathways COMP360 psilocybin, Usona psilocybin, and the Yale and Johns Hopkins programs, excludes participants with a personal history of Bipolar I or II, and most also exclude first-degree family history (MAPS, 2024). The exclusion is not bureaucratic caution. It is the conservative default based on a documented signal that classic psychedelics can precipitate mania in vulnerable individuals.
The trial designers are not in disagreement about the data. They are in agreement that the safety signal is real, that the population is small enough that excluding it does not compromise statistical power, and that adequately powered safety studies in bipolar populations need to be done separately before this exclusion can be reconsidered. Until those studies exist, the standard of care in research is exclusion.
What happens in retreat and underground contexts is different. Most operators ask only whether you have been diagnosed with bipolar disorder. The undiagnosed are not filtered. That is the gap this article exists to address. In my own practice across 900-plus sessions, careful screening has caught several presentations of probable undiagnosed Bipolar II before a session that, if it had gone ahead, could have produced a mania of unknown duration. Screening is not optional for this population.
According to consensus exclusion criteria adopted across MAPS, COMPASS Pathways, Usona, and Yale psychedelic research programs through 2024, both Bipolar I and Bipolar II disorders are absolute contraindications for trial enrollment, and a first-degree family history of bipolar disorder is a relative contraindication in most protocols. The shared rationale is the documented signal that 5-HT2A agonist psychedelics can precipitate manic, hypomanic, or mixed episodes in individuals with underlying bipolar pathology, with case-report estimates suggesting the absolute risk in bipolar populations exceeds 20 percent without mood stabilization, an order of magnitude above mixed-population rates. The mechanism is biologically plausible: 5-HT2A activation drives a downstream BDNF surge and elevates glutamatergic transmission in prefrontal-limbic circuits, the same plasticity window that produces therapeutic gain in unipolar depression but destabilizes mood regulation when a bipolar diathesis is already present. The clinical implication is that exclusion stays the conservative default until adequately powered safety trials in bipolar populations replicate the Aaronson 2024 monitoring conditions outside research settings.
What Does High-Functioning Hypomania Look Like in a Founder?
Bipolar II disorder affects approximately 0.4 percent of US adults and is misdiagnosed as recurrent unipolar depression for an average of 10 years before correct identification, according to Hirschfeld's foundational work on the Mood Disorder Questionnaire (Hirschfeld et al., 2000). The reason for the long misdiagnosis window is structural. People do not seek psychiatric care for hypomania. They seek care for the depressive episodes that follow it. The hypomania goes unreported and the picture stays incomplete.
The Productive Phase
Hypomanic episodes in Bipolar II last at least four consecutive days. The person needs less sleep but does not feel tired. Energy and confidence are elevated. Productivity often peaks. Thoughts move faster. Ideas connect easily. The person feels expansive, charismatic, and unusually capable. They start new projects. They commit to ambitious deliverables. They often produce real output during these periods, which is part of why the state is rarely flagged as pathological.
In the founder population this presentation has a name: "in the zone." It is what investors look for. It is what conferences celebrate. It is what high-performance culture treats as the aspirational state. The pattern is not always Bipolar II. Plenty of high performers are simply high performers. But the overlap means that the easiest way for hypomania to hide is to look like the cultural ideal of the founder.
The Crash That Follows
What distinguishes Bipolar II from sustainable high performance is what comes after the hypomanic period. The crash. A depressive episode arrives, sometimes within days, sometimes weeks later, and the affective state collapses below baseline. Sleep dysregulates. Motivation evaporates. Self-worth, which was elevated during hypomania, can become harshly negative. The founder interprets this as exhaustion or as burnout, books a vacation, and waits for it to lift. When it does lift, eventually, hypomania often returns, and the cycle continues.
The signal that this is bipolar rather than recurrent depression is the elevated state, not the depressed one. If the person has a history of distinct periods, lasting four or more days, of reduced sleep need plus elevated mood or irritability plus increased goal-directed activity, that is the diagnostic signature the screening instruments are built to detect.
How Can a Psychedelic Session Trigger a Manic Episode?
Classic serotonergic psychedelics act as 5-HT2A receptor agonists and produce a downstream surge in BDNF, altered prefrontal-limbic connectivity, and elevated glutamatergic transmission, all of which can destabilize an already vulnerable mood-regulation system. In an individual with an underlying bipolar diathesis, the same plasticity that produces therapeutic benefit in unipolar depression can tip the mood regulation system into a manic or hypomanic episode. The mechanism is well characterized at the receptor level even though the clinical risk profile in bipolar populations is still being mapped.
Acute Onset
Acute mania induction can begin during the session itself. The person may experience extreme grandiosity, racing thoughts that do not slow as the drug wears off, intense goal-directed energy, and sleep loss that persists for days. In retreat contexts this is sometimes celebrated as breakthrough or as awakening. In clinical contexts it is recognized as a treatment-emergent affective shift requiring urgent intervention. The distinction matters because the wrong frame extends the episode.
Delayed Onset
The more deceptive pattern is delayed onset. The session itself goes well. The person feels expansive and clear. Over the following one to three weeks, as the BDNF and plasticity window unfolds without adequate mood stabilization, the elevated state intensifies rather than settling. Sleep need drops. Behavior becomes increasingly disinhibited. Decisions get larger and faster. The person, and often the people around them, attribute this to post-session integration. By the time it becomes obvious that something has gone wrong, the episode is well established and harder to interrupt.
Risk Concentrators
The risk of psychedelic-induced mania is not evenly distributed. It concentrates in individuals with: undiagnosed Bipolar I or II, a first-degree family history of bipolar disorder, prior antidepressant-induced hypomania, current use of stimulant medications, severe sleep deprivation entering the session, and history of psychosis. Each of these is a screening question. None of them are reliably captured by the standard "have you ever been diagnosed with bipolar" intake form that many retreat operators use as their only filter.
Gard and colleagues (2024) synthesized case-report and trial-exclusion data across the modern psychedelic research literature and estimated that the rate of treatment-emergent manic or hypomanic episodes following psilocybin or LSD administration in mixed populations is approximately 4 to 9 percent, with risk concentrated almost entirely in participants with an underlying bipolar diathesis. The same review found that absolute risk in individuals who already meet criteria for a bipolar spectrum disorder, when given a psychedelic without mood stabilization, exceeds 20 percent in the available case series, supporting current exclusion criteria across MAPS, COMPASS, and Yale trials. Onset patterns split between acute mania emerging within hours of dosing and delayed episodes unfolding over the one-to-three-week BDNF plasticity window. Reported episode durations span several days to multiple months, with some cases requiring inpatient psychiatric admission. The clinical implication is that any pre-session screening protocol must capture not only diagnosed bipolar disorder but also family history, prior antidepressant-induced hypomania, and current stimulant use as independent risk concentrators.
What Does a Responsible Bipolar Screening Checklist Look Like?
The Mood Disorder Questionnaire developed by Hirschfeld and colleagues is the most widely validated brief bipolar screening instrument, with a sensitivity of approximately 73 percent and specificity of 90 percent for Bipolar I in psychiatric outpatient populations (Hirschfeld et al., 2000). The MDQ is not diagnostic on its own. It is a filter. A positive screen indicates the need for clinical evaluation by a psychiatrist before any psychedelic session. The questions below approximate the MDQ format and capture the bipolar spectrum signal that founder populations most often miss.
Has there ever been a period of time when you were not your usual self and:
- You felt so good or so hyper that other people thought you were not your normal self, or you were so hyper that you got into trouble?
- You were so irritable that you shouted at people or started fights or arguments?
- You felt much more self-confident than usual?
- You got much less sleep than usual and found you did not really miss it?
- You were much more talkative or spoke much faster than usual?
- Thoughts raced through your head or you could not slow your mind down?
- You were so easily distracted by things around you that you had trouble concentrating or staying on track?
- You had much more energy than usual?
- You were much more active or did many more things than usual?
- You were much more social or outgoing than usual, for example, telephoning friends in the middle of the night?
- You were much more interested in sex than usual?
- You did things that were unusual for you, or that other people might have thought were excessive, foolish, or risky?
- Spending money got you or your family into trouble?
Supplemental Screens
The HCL-32, hypomania checklist developed by Angst, is more sensitive than the MDQ for the Bipolar II end of the spectrum and is often used as a companion screen. The CIDI-based bipolar spectrum probes used in epidemiological studies are also more sensitive to subthreshold presentations. For a founder population, where the hypomania is the missing piece, layering the MDQ with the HCL-32 catches presentations that either instrument alone might miss.
What the Screen Cannot See
The honest limitation: a negative screen does not rule out bipolar disorder. The MDQ has a sensitivity of around 73 percent, which means roughly one in four Bipolar I cases will screen negative, and Bipolar II sensitivity is lower. The screen is a useful filter but not a final answer. The follow-up clinical evaluation matters at least as much, and in my experience the signal often emerges not in the answers themselves but in the way the person describes their best periods of work.
What Does the Aaronson 2024 Trial Actually Change?
Aaronson and colleagues published the first open-label trial of single-dose psilocybin in Bipolar II depression in JAMA Psychiatry in 2024, with 15 participants and intensive psychiatric monitoring, reporting clinically meaningful reductions in depression at three and twelve weeks with no treatment-emergent manic episodes during the observation period (Aaronson et al., JAMA Psychiatry, 2024). This is the first carefully monitored exception to the broad bipolar exclusion across psychedelic trials. The result is genuinely encouraging. It is also small, open-label, and run in a context that retreat settings cannot replicate.
What the trial demonstrates is that with rigorous screening, pre-session mood stabilization, controlled dose, structured psychotherapy support, and post-session psychiatric monitoring across the plasticity window, a meaningful subset of Bipolar II patients may be able to benefit from psilocybin without inducing a manic episode. What the trial does not demonstrate is that any of this transfers to a retreat in Costa Rica, a ceremony in Mexico, or an underground session where the participant disclosed their bipolar history and the operator decided to proceed anyway. The monitoring infrastructure that made the Aaronson result possible does not exist in those settings.
"The Aaronson trial is a careful experiment, not a permission slip. The conditions that made the outcome possible, the screening, the stabilization, the monitoring, are exactly the conditions that retreat contexts cannot reproduce. Reading the result as a green light for ceremonial use in bipolar populations is a misreading."
The reasonable interpretation of the trial is that future clinical protocols for Bipolar II depression are likely to emerge, that they will look more like the Aaronson design than like a retreat, and that the bipolar spectrum population may eventually have a research-grounded pathway. Until that pathway exists, the conservative recommendation for individuals with confirmed Bipolar I, Bipolar II, or strong family history remains the same: psychedelic sessions outside of a properly monitored clinical trial are contraindicated.
What Should You Do If Your Bipolar Screening Is Positive?
A positive bipolar screen is not a final diagnosis, but it is a hard stop on retreat-context psychedelic use until clinical evaluation is complete, and across 900-plus sessions of my own practice, I have learned that the founders who push past a positive screen rather than evaluating it are the ones most likely to encounter the kind of post-session disruption that this entire screening protocol exists to prevent. The next steps are concrete and sequential. None of them require giving up on the goal of working with these states. They require sequencing it correctly.
Merikangas and colleagues in the 2007 Archives of General Psychiatry national comorbidity survey replication established Bipolar I lifetime prevalence at 1.0% and Bipolar II at 1.1%, both lower than initial 2005 estimates but representing approximately 5.7 million US adults. Critically, Hirschfeld's research demonstrated that the average diagnostic delay from first hypomanic or manic episode to bipolar diagnosis is 8-12 years, with most patients incorrectly labeled as recurrent unipolar depression during this window. For founders specifically, the high-functioning, productive hypomanic state often gets reframed as "ambition" or "drive" rather than recognized as part of a bipolar cycle. This is exactly the population most at risk if psychedelics are introduced without proper screening for previously undetected bipolar diathesis.
Step One: Clinical Evaluation
A psychiatric evaluation with a clinician familiar with the bipolar spectrum is the first step. Bring the screening results. Bring an honest narrative of your best periods of work, not only the bad ones. The diagnostic question is whether your hypomanic-looking periods meet duration and impairment criteria for Bipolar I, Bipolar II, cyclothymia, or sub-threshold bipolar spectrum, or whether they represent high-functioning normal-spectrum variation. The clinical interview is the instrument that can answer this. The screening checklist cannot.
Step Two: Family History
A first-degree family history of Bipolar I or II is a separate risk factor that does not require a personal diagnosis to be operative. If a parent or sibling has confirmed bipolar disorder, the psychedelic risk profile is elevated even if your own screen is negative. The relevant question to the clinician becomes whether the family-history risk plus your specific presentation reaches a threshold where psychedelic use outside a monitored trial is contraindicated.
Step Three: Alternative Pathways
If the evaluation confirms bipolar spectrum or significant family-history risk, the responsible alternatives include: enrolling in a properly monitored clinical trial if eligibility allows, working with depression through non-psychedelic evidence-based treatments such as lamotrigine for the depressive pole, lithium-based protocols, or non-medication approaches such as IPSRT and CBT-BP, and addressing the founder-specific load conditions through methods that do not destabilize mood. The choice is not between a retreat and giving up. It is between a retreat and a less risky, often slower, pathway that does not roll the dice on a manic episode. For depression-specific framing, see psychedelic therapy for depression.
Step Four: If You Decide to Proceed Anyway
Some people, having seen all of the above, will still want to pursue a psychedelic session. The harm-reduction framing matters here. Disclose fully to whoever is running the session, even if you fear being turned away. Choose an operator who declines bipolar participants rather than one who accepts them, because the former is taking the risk seriously. Make sure mood stabilization is in place before the session and post-session psychiatric follow-up is scheduled. Identify a person who can detect early mania signs and has authority to intervene. For vetting retreat operators specifically, see how to vet a psychedelic retreat.